Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday

Neurogene (NASDAQ:NGNE) is expected to be posting its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Neurogene to post earnings of ($1.20) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Neurogene Stock Performance

Neurogene stock opened at $21.51 on Monday. The company has a market capitalization of $333.19 million, a P/E ratio of -5.23 and a beta of 1.53. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $37.27. The stock has a 50-day simple moving average of $19.05 and a 200-day simple moving average of $21.61.

Institutional Investors Weigh In On Neurogene

Institutional investors have recently modified their holdings of the company. Virtus Investment Advisers LLC grew its holdings in shares of Neurogene by 128.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 12,716 shares of the company’s stock worth $262,000 after acquiring an additional 7,138 shares during the period. Logos Global Management LP acquired a new position in Neurogene during the fourth quarter worth $4,017,000. Schonfeld Strategic Advisors LLC purchased a new stake in Neurogene during the fourth quarter worth $575,000. Trexquant Investment LP boosted its position in Neurogene by 9.7% during the fourth quarter. Trexquant Investment LP now owns 43,323 shares of the company’s stock worth $892,000 after purchasing an additional 3,840 shares in the last quarter. Finally, Blair William & Co. IL grew its holdings in Neurogene by 15.4% in the fourth quarter. Blair William & Co. IL now owns 163,655 shares of the company’s stock valued at $3,371,000 after purchasing an additional 21,835 shares during the last quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Analyst Ratings Changes

NGNE has been the topic of several research analyst reports. Canaccord Genuity Group began coverage on Neurogene in a research report on Friday, February 27th. They set a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Lifesci Capital began coverage on shares of Neurogene in a report on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price on the stock. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Neurogene in a research note on Tuesday, January 13th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.